<DOC>
	<DOC>NCT01576484</DOC>
	<brief_summary>This is a phase 2, open-label extension study to assess the long-term safety and efficacy of REGN727 (SAR236553) administered by subcutaneous (SC) injection in patients previously participating in the R727-CL-1003 study.</brief_summary>
	<brief_title>Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Key Inclusion Criteria 1. Prior participation in and the successful completion of the R727CL1003 study. 2. Patients must be on a stable daily statin regimen for at least 3 weeks before prior to entry into the study 3. A negative urine pregnancy at the screening/baseline visit for women of childbearing potential Key Exclusion Criteria 1. Reported a drugrelated SAE or drugrelated clinical or laboratory AE in the R727CL1003 study that resulted in early termination or withdrawal 2. Significant protocol deviation in R727CL1003, such as noncompliance by the investigator or patient 3. LDL apheresis within 12 months before the screening/baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>